SANOFI CONS HEALTHC IND L

NSE: SANOFICONR

Drug Manufacturers - GeneralHealthcareMID CAP•MCap ₹8.26k Cr

₹3,581.70₹-18.80 (-0.52%)

Market Closed • NSE

Market cap₹8.26k Cr

Enterprise value₹7.82k Cr

P/E TTM31.01

Forward P/E26.75

P/B23.71

EPS TTM₹115.49

Forward EPS₹133.90

ROE0.88%

ROA0.38%

D/E5.98

Dividend yield0.02%

52W high₹5,255.00

52W low₹3,540.00

Price chart(1Y)

1Y Return:-23.84% (₹1120.90)

H: ₹4,988.8L: ₹3,540

1W-4.56%

1M-11.55%

3M-21.93%

6M-23.79%

1Y-23.00%

Today at a glance

Day range

₹3,540.00₹3,619.00

52 week range

₹3,540.00₹5,255.00

Volume5.8K0.86x 20D avg

Free float50.00%-13.50% volume

SANOFI CONS HEALTHC IND L closed at INR3581.70 (-0.52%) on volume 0.86x its 20-day average, trading 31.84% below its 52-week high.

Technical analysis

RSI (14)15.7Oversold

MACDBEARISHBearish (Below signal)

ATR (14)₹102.67Moderate

SMA 20₹3,896.08BEARISH

SMA 50₹4,152.99BEARISH

SMA 100₹4,400.12BEARISH

SMA 200₹4,405.78BEARISH

CPR bottom₹3,649.35

Pivot₹3,633.07

CPR top₹3,616.78

What changed recently?

2026-Q1

Q1 FY2026 Financial Results

PAT moved +2% QoQ

2026-06-19

DIVIDEND Announced

Dividend - Rs 75 Per Share

2025-04-17

DIVIDEND Announced

Dividend - Rs 55 Per Share

Shariah audit

Methodology: AAOIFI Shariah Standard No. 21

PASS4/4 criteria

Shariah Compliant

Criteria	Numerator	Denominator	Value	Threshold	Status
Interest-bearing debt ratio	₹24.8 Cr	₹8.26k Cr	0.30%	≤ 33%	PASS
Non-halal income ratio	₹15.2 Cr	₹878.0 Cr	1.73%	≤ 5%	PASS
Illiquid assets ratio	₹172.2 Cr	₹547.0 Cr	31.48%	≥ 20%	PASS
Receivables ratio	–	₹547.0 Cr	—	≤ 49%	PASS

Valuation & sector context

MetricCompanySector

P/E31.0137.60

Forward P/E26.75—

P/B23.715.10

EV/EBITDA—18.00

PEG—1.00

Earnings yield3.202.70

Growth & profitability

RevenuePAT

FY23PAT margin 30.30%

FY24PAT margin 25.00%

FY25PAT margin 27.30%

Revenue and PAT bars use independent scales to make their year-on-year direction readable.

Revenue CAGR 3Y+6.60%

Revenue CAGR 5Y—

PAT CAGR 3Y+9.90%

PAT CAGR 5Y—

Operating margin36.49%

Net margin28.01%

Financial health & cash flow

Net debt–Moderate

Interest coverage141.60xEBIT / interest

CFO / PAT1.46x3Y average

Net debt / EBITDA—Leverage

Operating cash flow₹174.8 Cr

Capital expenditure–

Free cash flow₹167.2 Cr

Financial statements

Complete reported financial history · Values use the company's reporting currency

Hover over the chart for exact reported values. Percentage lines use the right-hand axis.

Fundamental scorecard

Overall65/100

Valuation50/100

Profitability50/100

Financial health95/100

A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.

Strengths, risks & investment thesis

Strengths

Low Debt Profile: Debt-to-Equity is comfortable at 0.06x

High Cash Flow Conversion: CFO/PAT averaged 1.46x over last 3 years

Risks

Subject to cyclical raw material and macro industry pressures

Bull case

Market Leadership: Established operational scale in Drug Manufacturers - General.

Bear case

Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.

Flip condition

Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.

Shareholding pattern

Quarterly ownership historyLatest valid period · December 2024

Ownership distribution

Dec 2024Latest holding

Category trends

Hover over a period for exact holdings

20.45%Institutional holding

8.28%Public holding

2Periods available

0.00%Promoter pledged

47.51KShareholders

Corporate Action

Complete dividend, bonus, split, rights and other action history

Record date	Corporate action	Information	Announcement date	Ex-date
19 Jun 2026	Dividend	₹75.00 / share	—	19 Jun 2026
17 Apr 2025	Dividend	₹55.00 / share	—	17 Apr 2025

Delivery participation

Traded volume and delivery percentage across the latest 20 sessions

Average delivery (20D)52.00%-10.67% latest vs average

Highest delivery65.01%on 18 Sept

Average volume (20D)6.7KTrading-session average

Conviction trendWeakening-10.67% latest reading

Traded volumeDelivery %

Peer comparison

Compare valuation, latest quarterly performance and year-on-year growth

8 companies

Company name	Market cap ₹ Cr	P/E ratio	Dividend yield %	Quarterly sales ₹ Cr	Profit after tax ₹ Cr	Sales growth %	Profit growth %
Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis	₹4.22L	34.92	0.91%	₹15,300.00	₹2,901.00	+10.46%	+26.52%
Divi's Laboratories LimitedDIVISLAB Open analysis	₹2.48L	84.75	0.32%	₹3,080.00	₹902.00	+27.80%	+65.50%
Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis	₹1.77L	74.39	0.82%	₹4,128.00	₹389.00	+41.90%	-21.89%
LENSKART SOLUTIONS LTDLENSKART Open analysis	₹1.17L	183.15	0.00%	₹2,714.00	₹228.00	+43.29%	+273.77%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis	₹1.15L	55.26	0.26%	₹7,044.00	₹610.00	+20.58%	+38.32%
Zydus Lifesciences LimitedZYDUSLIFE Open analysis	₹1.11L	24.91	0.09%	₹8,017.00	₹990.00	+21.95%	-34.91%
Laurus Labs LimitedLAURUSLABS Open analysis	₹1.10L	100.67	0.12%	₹2,026.31	₹367.60	+29.10%	+125.49%
Cipla LimitedCIPLA Open analysis	₹1.05L	31.20	0.99%	₹7,119.00	₹786.00	+2.33%	-39.16%

About SANOFI CONS HEALTHC IND L

Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products.[1]It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]

IndiaHealthcare

Questions investors ask

Is SANOFI CONS HEALTHC IND L Shariah compliant?

SANOFI CONS HEALTHC IND L is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.3%) complies with AAOIFI threshold (≤ 33%).

What is SANOFI CONS HEALTHC IND L's current valuation relative to peers?

SANOFI CONS HEALTHC IND L trades at a P/E of 31.0x compared to the sector median of 37.6x, and a Price-to-Book of 23.7x.

Is the company financially healthy?

The company has a Debt-to-Equity ratio of 0.06x. Interest coverage is 141.6x.

What are the historical revenue and profit growth rates?

Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.

Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.

Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.